Skip to main content


Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Figure 3 | Theoretical Biology and Medical Modelling

Figure 3

From: Modeling drug resistance in a conjoint normal-tumor setting

Figure 3

The evolution of normal and tumor cells during the phase of therapy in a chemo-resistance setting. In this figure the blue, red, and purple curves illustrate the evolution of the normal population, the drug responsive tumor cell population, and the drug resistant tumor cell population respectively. a) The behavior of the coupled normal-tumor cells in the absence of drug resistant tumor cells and with no chemotherapy is simulated when K T = K N = 106, r T = 0.25 r n = 0.5, κ = 0.124, T* C = 5*105. b) The conjoint normal-tumor cells are now simulated in the presence of an anti-tumor drug. The fraction killing rate is considered to be constant with the value of a T (1-e-MC) = 0.1, and the treatment is started at t = 50 days. It is assumed that the administered drug has no effect on normal cells; a N (1-e-MC) = 0. c) the drug resistance conjoint model in which the tumor cells are categorized either as drug responsive or drug resistant is simulated when K T = K N = K R = 1*106, r T = 0.25 r n = 0.5, r R = 0.1, κ = 0.124, T* C = 5*105, μ = 10−3. d) The three component model is simulated as the system interacts with an anti-tumor drug effective only on the drug responsive tumor cells, a T (1-e-MC) = 0.1 at t = 50 days. e) In this figure, the dynamics of the three-component is simulated where the system is treated with two distinct drugs, one effective only on drug responsive tumor cells and one on the drug resistant tumor cells when a T (1-e-MC) = 0.1 and a R (1-e-MC) = 0.02 and both treatments are started at t = 50. f) A similar treatment to that of Figure e is simulated at t = 5 days.

Back to article page